This article provides a thorough overview of the pathophysiology and current treatment options for myasthenia gravis, an autoimmune and antibody-mediated neuromuscular disease.

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the acetylcholine receptor (AChR ...

In the U.S., More People Are Dying from Myasthenia Gravis —That’s the main take-away from a new study, which investigated mortality trends among patients with myasthenia gravis from 1999 to ...

ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis ...

Vor Bio is licensing global rights to a fusion protein that inhibits two targets to potentially treat the neuromuscular disorder generalized myasthenia gravis. It’s a pivot for Vor, which last ...

Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction. In approximately 80% of patients, auto-antibodies to the muscle nicotinic acetylcholine receptor ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis ...

Philanthropist Mike Fernandez protests FIU’s tuition hike for undocumented students, calling it unfair and reversing on years of progress.

Macarthur Minerals Limited (MIO), an ASX-listed company, is an iron ore development, and lithium exploration company that is focused on bringing to production its Western Australia iron ore projects.

It’s a well-known aria from a not-particularly-famous opera. But what are the lyrics to Puccini’s ‘O mio babbino caro’?

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

Advances in the Treatment of Myasthenia Gravis Nils Erik Gilhus Disclosures Future Neurology. 2012;7 (6):701-708. Symptomatic Treatment ...